Author

Anuradha Pandit

University of MinnesotaORCID 0000-0002-7633-1178Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 2 Approach:experimental assay· 2 Organism:human· 2 Research Focus:cell signaling & trafficking· 1 Research Focus:drug response / drug discovery· 1 Assay:metabolomics· 1 Assay:proteomics· 1 Approach:wet-lab / biochemical assay· 1

Frequent Co-Authors

Luke H. HoeppneriD· 2 shared Sk. Kayum AlamiD· 2 shared Brittney ThieleiD· 1 shared Charles M. RudiniD· 1 shared Li WangiD· 1 shared Li WangiD· 1 shared Marie Christine Aubry· 1 shared Parvathy ManojiD· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 30 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Luke H. HoeppnerORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Primary cilia promote resistance to EGFR tyrosine kinase inhibitor, osimertinib, in non-small cell lung cancer

Li Wang, Anuradha Pandit, Sk. Kayum Alam, Rhiannon Skauge, Sergio A. Gradilone, Luke H. Hoeppner

This study shows that primary cilia formation contributes to resistance to osimertinib in EGFR-mutated NSCLC by promoting sodium influx and HDAC6 inactivity, and that targeting ciliogenesis can reverse resistance.

bioRxiv · Mar 5, 2026 · PreprintCancer Biology

Dopamine D2 receptor agonists abrogate neuroendocrine tumour angiogenesis to inhibit chemotherapy-refractory small cell lung cancer progression

Sk. Kayum Alam, Anuradha Pandit, Li Wang, Seyedeh Sahar Mortazavi Farsani, Brittney Thiele, Parvathy Manoj, Marie Christine Aubry, Vivek Verma, Charles M. Rudin, Ying‐Chun Lo, Luke H. Hoeppner

This study shows that dopamine D2 receptor agonists reduce angiogenesis and inhibit chemotherapy-refractory small cell lung cancer progression by targeting tumour-associated endothelial cells.

Cell Death and Disease · May 9, 2025Peer-reviewedCancer Biology